Skyrizi ® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Skyrizi is now available as a single-dose 150 mg ...

The approval was based on data from 2 pivotal phase 3 studies, which compared Skyrizi to placebo in adults with active PsA who had an inadequate response or were intolerant to biologic therapy and/or ...

After Rinvoq won two new indications in as many months, AbbVie's immunology compatriot Skyrizi is getting in on the approval action. Skyrizi clinched a second nod, this time to treat adults with ...

Skyrizi is used to treat certain inflammatory conditions, such as plaque psoriasis. The drug starts working after your first dose. The Food and Drug Administration (FDA) has approved Skyrizi to treat ...

Please provide your email address to receive an email when new articles are posted on . Patients that were white, Black, Asian or “other” achieved similar efficacy results with Skyrizi. Similar ...

Feb 2 (Reuters) - AbbVie Inc (ABBV.N), opens new tab forecast full-year adjusted profit above Wall Street estimates on Wednesday, as strong sales of its blockbuster anti-wrinkle injection Botox and ...

AbbVie’s immunology stalwart Skyrizi continued its ascent Friday, as the drug clinched a third indication and its second FDA approval of the year. Thanks to a thumbs up from the U.S.’ drug regulator, ...